Allelic loss of 16q23.2-24.2 is an independent marker of good prognosis in primary breast cancer.
Allelic loss, detected as a loss of heterozygosity (LOH) on the long arm of chromosome 16, is an early and frequent event in breast cancer. Despite this, the clinical significance of LOH on 16q has been very poorly studied. In this study, corresponding blood and tumor samples from 199 clinically well-characterized primary breast cancer patients were analyzed for LOH with the highly polymorphic microsatellite marker D16S511, located at 16q23.2-24.2. 61% of 168 informative tumors showed LOH. Univariate and multivariate analysis found a highly significant association between LOH at 16q23.2-24.2 and freedom from distant metastases, disease-free survival, and overall survival, respectively. No association was found with other clinical parameters such as menopausal status, tumor size, lymph node status, histopathology, and lymph node capsule invasion. This makes allelic loss of 16q23.2-24.2 an independent marker of good prognosis for primary breast cancer.
Hansen
L L
LL
Institute of Human Genetics, Aarhus University, Aarhus C, Denmark. Lotte@humgen.aau.dk
Yilmaz
M
M
Overgaard
J
J
Andersen
J
J
Kruse
T A
TA
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000235:genetics*; D002885:Chromosomes, Human, Pair 16 / Q000235:genetics*; D018572:Disease-Free Survival; D005260:Female; D005819:Genetic Markers / Q000235:genetics*; D006801:Humans; D019656:Loss of Heterozygosity / Q000235:genetics*; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models
D005819:Genetic Markers